Hartman Institute for Therapeutic Organ Regeneration

Molecular Checkpoint Decisions Made by Subverted Vascular Niche Transform Indolent Tumor Cells into Chemoresistant Cancer Stem Cells.

TitleMolecular Checkpoint Decisions Made by Subverted Vascular Niche Transform Indolent Tumor Cells into Chemoresistant Cancer Stem Cells.
Publication TypeJournal Article
Year of Publication2017
AuthorsCao Z, Scandura JM, Inghirami GG, Shido K, Ding B-S, Rafii S
JournalCancer Cell
Volume31
Issue1
Pagination110-126
Date Published2017 Jan 09
ISSN1878-3686
KeywordsAnimals, Cell Transformation, Neoplastic, Drug Resistance, Neoplasm, Endothelial Cells, Fibroblast Growth Factor 4, Humans, Insulin-Like Growth Factor Binding Proteins, Insulin-Like Growth Factor I, Mice, Neoplastic Stem Cells, Proto-Oncogene Protein c-ets-2, Receptor, IGF Type 1
Abstract

<p>Tumor-associated endothelial cells (TECs) regulate tumor cell aggressiveness. However, the core mechanism by which TECs confer stem cell-like activity to indolent tumors is unknown. Here, we used in vivo murine and human tumor models to identify the tumor-suppressive checkpoint role of TEC-expressed insulin growth factor (IGF) binding protein-7 (IGFBP7/angiomodulin). During tumorigenesis, IGFBP7 blocks IGF1 and inhibits expansion and aggresiveness of tumor stem-like cells (TSCs) expressing IGF1 receptor (IGF1R). However, chemotherapy triggers TECs to suppress IGFBP7, and this stimulates IGF1R TSCs to express FGF4, inducing a feedforward FGFR1-ETS2 angiocrine cascade that obviates TEC IGFBP7. Thus, loss of IGFBP7 and upregulation of IGF1 activates the FGF4-FGFR1-ETS2 pathway in TECs and converts naive tumor cells to chemoresistant TSCs, thereby facilitating their invasiveness and progression.</p>

DOI10.1016/j.ccell.2016.11.010
Alternate JournalCancer Cell
PubMed ID27989801
PubMed Central IDPMC5497495
Grant ListR01 HL128158 / HL / NHLBI NIH HHS / United States
R01 DK095039 / DK / NIDDK NIH HHS / United States
R01 HL097797 / HL / NHLBI NIH HHS / United States
R01 HL130826 / HL / NHLBI NIH HHS / United States
R01 HL119872 / HL / NHLBI NIH HHS / United States
R56 HL116436 / HL / NHLBI NIH HHS / United States

Weill Cornell Medicine
Hartman Institute for Therapeutic Organ Regeneration
1300 York Ave, Box 136 New York, NY 10065